Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necro...
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
- Associated Therapies
- -
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
- Conditions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT00754780
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1058
- Registration Number
- NCT00662038
- Locations
- 🇺🇸
Genentech, Inc., South San Francisco, California, United States
Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 32
- Registration Number
- NCT00332033
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 435
- Registration Number
- NCT00287716
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT00287729
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT00080223
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00076102
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Childrens Hospital, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸St. Louis Children's Hospital, Saint Louis, Missouri, United States
Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes
- First Posted Date
- 2003-07-02
- Last Posted Date
- 2009-11-04
- Lead Sponsor
- Sharma, Kumar, M.D.
- Target Recruit Count
- 77
- Registration Number
- NCT00063583
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Bethesda, Maryland, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The Center for Diabetic Kidney Disease at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00053937
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020631
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.